Shopping Cart
Remove All
Your shopping cart is currently empty
Abciximab (Synonyms: C7E3)
Catalog No. T76844 Copy Product Info
🥰Excellent
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.
Abciximab
Copy Product Info🥰Excellent
Catalog No. T76844
Synonyms C7E3
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.
Abciximab
Cas No. 143653-53-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | In Stock | In Stock | |
| 5 mg | $563 | - | In Stock | |
| 10 mg | $886 | - | In Stock | |
| 25 mg | $1,330 | - | In Stock | |
| 50 mg | $1,780 | - | In Stock | |
| 100 mg | $2,430 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.5% (SDS-PAGE); 95.9% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors. |
| In vitro | Inhibiting platelet aggregation induced by physiologic and pathologic agonists, abciximab (C7E3) achieves this effect by binding to the platelet αIIbβ3 integrin[2]. Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2]. |
| In vivo | Effectively preventing neointimal hyperplasia, abciximab (C7E3) is administered at a dose of 0.25 mg/kg/day via intravenous infusion for 28 days[2]. |
| Synonyms | C7E3 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | glycoprotein (GP) IIb/IIIa |
| Molecular Weight | 95.18 kDa |
| Cas No. | 143653-53-6 |
| Isotype | Fab-IgG1-CH1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Abciximab | purchase Abciximab | Abciximab cost | order Abciximab | Abciximab in vivo | Abciximab in vitro | Abciximab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.